Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | January 19, 2023 |
| Target | Concert Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Sun Pharma |
| Deal Type | Add-on Acquisition |
| Deal Value | 576M USD |
| Advisor(s) | MTS Health Partners Chestnut Partners (Financial) Goodwin Procter (Legal) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1983 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 520.4B INR (2025) |
Sun Pharma is a specialty generic pharmaceutical company. Products are sold through drug stores, mass merchants, grocery stores, and gift/specialty stores. Sun Pharma was founded in 1983 and is based in Mumbai, Maharashtra.
| Deal Context for Buyer | # |
|---|---|
| Overall | 14 of 15 |
| Sector: Life Science | 9 of 10 |
| Type: Add-on Acquisition | 7 of 8 |
| State: Massachusetts | 3 of 4 |
| Country: United States | 6 of 7 |
| Year: 2023 | 1 of 1 |
| Size (of disclosed) | 2 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-11-27 |
Pola Pharma
Shinagawa, Japan Pola Pharma, Inc. is a pharmaceutical company to healthier, more beautiful skin. Pola Pharma has two factories in Japan to make topical products and injectables. It has research and development capabilities to develop new technologies and formulations. Pola Pharma, Inc. was founded in 2007 and is based in Shinagawa, Japan. |
Buy | $1M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-03-09 |
Checkpoint
Waltham, Massachusetts, United States Checkpoint is a commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. It has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Checkpoint is based in Waltham, Massachusetts. |
Buy | $355M |
